Skip to main content

Table 2 Comparison of liver transplant recipients who did and did not undergo liver biopsy

From: Liver biopsy is still needed in liver transplantation recipients: a single center experience

 

Recipients (n = 89)

 

p

Non-biopsied

Biopsied

n = 55 (61.8%)

n = 34 (38.2%)

Age years

46.96 ± 8.74

44.65 ± 8.46

 

0.222

MELD

8.82 ± 2.86

8.74 ± 4.71

 

0.258#

ALBI score

− 2.96 ± 0.50

− 2.62 ± 0.60

 

0.014#

Follow-up months

38.40 ± 20.42

51.53 ± 15.92

 

0.001#

Sex

 Male

53 (96.4%)

30 (88.2%)

83 (93.3%)

0.197

 Female

2 (3.6%)

4 (11.8%)

6 (6.7%)

Indication of LT

 HCV

33 (60%)

21 (61.8%)

54 (60.7%)

0.192

 HCV + HCC

18 (32.7%)

10 (29.4%)

28 (31.5%)

 HBV

4 (7.3%)

0

4 (4.5%)

 HCV + HBV + HCC

0

1 (2.9%)

1 (1.1%)

 PSC

0

1 (2.9%)

1 (1.1%)

 AIH

0

1 (2.9%)

1 (1.1%)

  1. MELD model for end-stage liver disease, ALBI albumin-bilirubin, HCV hepatitis C virus, HBV hepatitis B virus, HCC hepatocellular carcinoma, PSC primary biliary cholangitis, AIH autoimmune hepatitis
  2. #Mann–Whitney U test